Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Calgary

$17,500.00

Enhancing T cell-based treatments in breast cancer using engineered type 2 innate lymphoid cells

FY 2023-24

Summary
Breast cancer is the most common cancer affecting women in Canada and is the second leading cause of death from cancer in Canadian women. This translates into one Canadian woman succumbing to this disease every 90 minutes. In recent years, advances to cancer treatment have been made with therapies using effector T cells, a type of white blood cell. The ability to genetically engineer effector T cells have made them powerful killers of tumour cells. However, only a fraction of breast cancer patients have benefited from these treatments. In breast cancer, local immunosuppressive mechanisms and the limited capacity of T cells to infiltrate breast cancer tumours deeply weaken effector T cell function, limiting the effector T cells' ability to reach their targets and eliminate tumour cells. Consequently, many patients suffer from untreatable relapses and have exhausted their treatment options. Thus, alternative targets and treatments that give patients a second chance to eradicate cancer are urgently needed. Our research has revealed that type 2 innate lymphoid cells (ILC2s), another type of white blood cell, have the potential to improve the recruitment and ability of effector T cells to eradicate breast cancer tumours. Here, we propose to engineer ILC2s to further increase their capacity to enhance T cell-based treatment efficacy in breast cancer. Specifically, this project seeks to i) use cutting-edge genome editing tools to genetically engineer ILC2s, and ii) to verify the successful engineering and the functions of the engineered ILC2s in cell culture. Collectively, this innovative approach has the potential to improve T cell-based treatment efficacy for breast cancer, improving breast cancer patient outcomes.
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
506143
Name
Kinzel Megan E
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Enhancing T cell-based treatments in breast cancer using engineered type 2 innate lymphoid cells
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Genetic Engineering; Immunotherapy; Innate Lymphoid Cells; Tumour Microenvironment
Abstract
Breast cancer is the most common cancer affecting women in Canada and is the second leading cause of death from cancer in Canadian women. This translates into one Canadian woman succumbing to this disease every 90 minutes. In recent years, advances to cancer treatment have been made with therapies using effector T cells, a type of white blood cell. The ability to genetically engineer effector T cells have made them powerful killers of tumour cells. However, only a fraction of breast cancer patients have benefited from these treatments. In breast cancer, local immunosuppressive mechanisms and the limited capacity of T cells to infiltrate breast cancer tumours deeply weaken effector T cell function, limiting the effector T cells' ability to reach their targets and eliminate tumour cells. Consequently, many patients suffer from untreatable relapses and have exhausted their treatment options. Thus, alternative targets and treatments that give patients a second chance to eradicate cancer are urgently needed. Our research has revealed that type 2 innate lymphoid cells (ILC2s), another type of white blood cell, have the potential to improve the recruitment and ability of effector T cells to eradicate breast cancer tumours. Here, we propose to engineer ILC2s to further increase their capacity to enhance T cell-based treatment efficacy in breast cancer. Specifically, this project seeks to i) use cutting-edge genome editing tools to genetically engineer ILC2s, and ii) to verify the successful engineering and the functions of the engineered ILC2s in cell culture. Collectively, this innovative approach has the potential to improve T cell-based treatment efficacy for breast cancer, improving breast cancer patient outcomes.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kinzel, Megan E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~